DE69307895T2 - Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin - Google Patents

Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin

Info

Publication number
DE69307895T2
DE69307895T2 DE69307895T DE69307895T DE69307895T2 DE 69307895 T2 DE69307895 T2 DE 69307895T2 DE 69307895 T DE69307895 T DE 69307895T DE 69307895 T DE69307895 T DE 69307895T DE 69307895 T2 DE69307895 T2 DE 69307895T2
Authority
DE
Germany
Prior art keywords
sphingosine
phosphoryl
serine
acyl
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69307895T
Other languages
English (en)
Other versions
DE69307895D1 (de
Inventor
Aurelio Romeo
Guenter Kirschner
Gianpaolo Menon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia SpA filed Critical Fidia SpA
Publication of DE69307895D1 publication Critical patent/DE69307895D1/de
Application granted granted Critical
Publication of DE69307895T2 publication Critical patent/DE69307895T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69307895T 1992-08-03 1993-08-02 Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin Expired - Fee Related DE69307895T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITPD920145A IT1260155B (it) 1992-08-03 1992-08-03 Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
PCT/EP1993/002061 WO1994003178A1 (en) 1992-08-03 1993-08-02 Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine

Publications (2)

Publication Number Publication Date
DE69307895D1 DE69307895D1 (de) 1997-03-13
DE69307895T2 true DE69307895T2 (de) 1997-08-14

Family

ID=11390037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69307895T Expired - Fee Related DE69307895T2 (de) 1992-08-03 1993-08-02 Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin

Country Status (10)

Country Link
US (1) US5556843A (de)
EP (1) EP0652755B1 (de)
JP (1) JPH07509478A (de)
AT (1) ATE148345T1 (de)
AU (1) AU4706293A (de)
CA (1) CA2141557A1 (de)
DE (1) DE69307895T2 (de)
ES (1) ES2101334T3 (de)
IT (1) IT1260155B (de)
WO (1) WO1994003178A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
EP0821068A3 (de) * 1996-03-29 1999-06-02 Rohm And Haas Company Sphingolipide and Verfahren dazu
EP1293124A3 (de) * 1996-03-29 2003-04-09 Dow AgroSciences LLC Verfahren zur Behandlung von Planzen mit Sphingolipiden
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
CA2355645A1 (en) * 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Increasing brain glucose utilization
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
AR074061A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica
KR20170025909A (ko) 2015-08-31 2017-03-08 가천대학교 산학협력단 스핑고신 1-인산 또는 Sphk2의 발현을 상승시키는 물질을 포함하는 대사 기능 장애의 예방 또는 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135720A (ja) * 1987-11-20 1989-05-29 Eisai Co Ltd 神経線維再生剤

Also Published As

Publication number Publication date
ATE148345T1 (de) 1997-02-15
EP0652755A1 (de) 1995-05-17
AU4706293A (en) 1994-03-03
IT1260155B (it) 1996-03-28
CA2141557A1 (en) 1994-02-17
US5556843A (en) 1996-09-17
WO1994003178A1 (en) 1994-02-17
ITPD920145A1 (it) 1994-02-03
ITPD920145A0 (it) 1992-08-03
EP0652755B1 (de) 1997-01-29
ES2101334T3 (es) 1997-07-01
DE69307895D1 (de) 1997-03-13
JPH07509478A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
FI941022A (fi) Spirosykliset piperidiinijohdannaiset
SG55184A1 (en) New imidazopyridines
DE69326250D1 (de) Neuropeptide y antagoniste
FI932229A (fi) Azabicykliska bryggderivat
MX9601360A (es) Mezcla estabilizante sinergistica.
AP9200410A0 (en) Retroviral protease inhibitors.
ES2111925T3 (es) Piridinas herbicidas sustituidas con heterociclos.
ATE148345T1 (de) Therapeutische verwendung von phosphoryl-l-serin- n-acyl-sphingosin
MX9801190A (es) Inhibidores de prolil endopeptidasa.
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
FI952855A0 (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
ATE206127T1 (de) Inhibitoren retroviraler proteasen
DK0850225T3 (da) Mellemprodukt til fremstilling af en farmaceutisk aktiv forbindelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee